Loading
A phase 3 trial of pembrolizumab and olaparib in triple-negative breast cancer, run by The Netherlands Cancer Institute, not yet recruiting.
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy is a phase 3, randomised interventional study registered as NCT07486687 by The Netherlands Cancer Institute, with a registry enrolment figure of 1000 participants, started 2026-04 and due to reach its primary completion in 2032-04. Interventions recorded: Standard of care plus pembrolizumab; Standard of care (capecitabine or olaparib). Conditions listed: Triple Negative Breast Cancer (TNBC), Early Setting; Early Stage Triple-Negative Breast Carcinoma; Triple -Negative Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III. Triple-negative eligibility wording from the registry: "Stage II or III TNBC prior to the start of neoadjuvant treatment". No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PARP inhibitors, Olaparib, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Pembrolizumab, Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares PARP inhibitors, Olaparib, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/